Login / Signup

Impact of Sacubitril/Valsartan on the Long-Term Incidence of Ventricular Arrhythmias in Chronic Heart Failure Patients.

Ibrahim El-BattrawyChristina PilsingerVolker LiebeSiegfried LangJürgen KuschykXiao-Bo ZhouMartin BorggrefeSusanne RögerIbrahim Akin
Published in: Journal of clinical medicine (2019)
Sacubitril/valsartan does not reduce the risk of ventricular tachyarrhythmias in chronic HFrEF patients over 12 months of follow-up.
Keyphrases
  • ejection fraction
  • heart failure
  • left ventricular
  • end stage renal disease
  • newly diagnosed
  • risk factors
  • catheter ablation
  • patient reported outcomes
  • atrial fibrillation